ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
Mitsubishi Tanabe: PharmaVitae forecasts at a glance 8
Mitsubishi Tanabe: PharmaVitae forecasts at a glance 8
Strategic insight 9
2002-06: Tanabe's historical sales driven by Remicade uptake 9
2007: Tanabe and Mitsubishi merger - amid a wave of Japanese consolidation 10
2008-14: Greater scale, but slow growth 11
SWOT analysis 12
Strengths 12
Weaknesses 12
Opportunities 13
Threats 13
Table of Contents 14
Table of figures 16
Chapter 3 Quarterly update 17
Latest prescription pharma product news 17
Q1 2010 17
Q4 2009 17
Q3 2009 17
Q2 2009 17
Q1 2009 17
Q4 2008 17
Latest corporate news 18
Q1 2010 18
Q3 2009 18
Q2 2009 18
Q1 2009 18
Q4 2008 18
Future product milestones 18
Chapter 4 Company introduction 20
Key findings 20
Background 21
Key corporate developments 21
M&A history 21
Merger of Mitsubishi Pharma and Tanabe Seiyaku 22
M&A history - Mitsubishi Pharma 23
Acquired by Mitsubishi Chemical Corporation 23
Divestment of OTC franchise 23
Divestment of US plasma fractionation business 23
M&A history - Tanabe Seiyaku 23
Animal Health Business Transferred from Tanabe to Dainippon 23
M&A strategy 24
Increase in US presence 24
Strengthen reputation in Japan 24
Current corporate structure 25
Pharmaceuticals segment 25
Other business segment 25
Chapter 5 Company sales 26
Key findings 26
Prescription pharmaceutical sales and growth rate analysis, 2002-14 27
Product analysis 29
Product analysis 29
Product analysis, 2002-08 30
Product analysis, 2008-14 33
Therapy area analysis 36
Geographic analysis 39
Launch/core/expiry analysis 41
Explanation of launch/core/expiry analysis 41
Launch analysis, 2008-14 42
Core analysis, 2008-14 43
Expiry analysis, 2008-14 45
Launch/core/expiry configuration, 2008-14 46
Molecule type analysis 47
Externalization analysis 49
Chapter 6 Company financials 51
Key findings 51
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 52
Operating costs and profit analysis 53
Operating costs and profit analysis, 2002-08 54
Operating cost ratio and profit margin analysis, 2002-08 55
Operating cost ratio and profit margin analysis, 2008-14 56
Operating costs and profit analysis, 2008-14 57
Chapter 7 Appendix 58
Abbreviations 58
Exchange rates 59
About Datamonitor 60
About Datamonitor Healthcare 60
Datamonitor consulting 60
Disclaimer 62
List of Tables
Table 1: Mitsubishi Tanabe - PharmaVitae forecasts at a glance 8
Table 2: Mitsubishi Tanabe upcoming milestones 18
Table 3: Mitsubishi Tanabe product portfolio overview ($m), 2002-08 30
Table 4: Mitsubishi Tanabe product portfolio overview ($m), 2008-14 33
Table 5: Mitsubishi Tanabe prescription pharmaceutical sales by therapy area ($m), 2008-14 37
Table 6: Mitsubishi Tanabe prescription pharmaceutical sales by geographic region ($m), 2008-14 40
Table 7: Mitsubishi Tanabe launch portfolio overview ($m), 2008-14 42
Table 8: Mitsubishi Tanabe core portfolio overview ($m), 2008-14 43
Table 9: Mitsubishi Tanabe expiry portfolio overview ($m), 2008-14 45
Table 10: Mitsubishi Tanabe prescription pharmaceutical sales by molecule type ($m), 2008-14 48
Table 11: Mitsubishi Tanabe prescription pharmaceutical sales by source ($m), 2008-14 50
Table 12: Total Mitsubishi Tanabe sales by business unit ($m), 2002-08 52
Table 13: Mitsubishi Tanabe operating revenue/cost analysis ($m), 2002-08 54
Table 14: Mitsubishi Tanabe operating cost ratio analysis (% of total revenues), 2002-08 55
Table 15: Mitsubishi Tanabe operating cost ratio analysis (% of total revenues), 2008-14 56
Table 16: Mitsubishi Tanabe operating revenue/cost analysis ($m), 2008-14 57
Table 17: Exchange rates, 2009 59
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: Mitsubishi Tanabe prescription pharmaceutical sales ($m) and growth rate (%) 2002-14 6
Figure 3: Mitsubishi Tanabe's financial performance ($m), 2002-14 7
Figure 4: Tanabe Seiyaku's historical prescription pharmaceutical performance, 2002-06 ($m) 9
Figure 5: Japan Pharma peer set, company ranking by prescription pharmaceutical sales, 2002-14 ($m) 10
Figure 6: Mitsubishi Tanabe prescription pharmaceutical sales by source, 2002-14, ($m) 11
Figure 7: Mitsubishi Tanabe SWOT analysis 12
Figure 8: M&A/divestment history 21
Figure 9: Current corporate structure 25
Figure 10: Mitsubishi Tanabe prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 27
Figure 11: Key product sales ($m), 2002-14 29
Figure 12: Mitsubishi Tanabe key sales growth drivers and resistors ($m), 2002-08 32
Figure 13: Mitsubishi Tanabe key sales growth drivers and resistors ($m), 2008-14 35
Figure 14: Mitsubishi Tanabe prescription pharmaceutical sales by therapy area ($m), 2002-14 36
Figure 15: Mitsubishi Tanabe prescription pharmaceutical sales by geographic region ($m), 2002-14 39
Figure 16: Mitsubishi Tanabe launch/core/expiry configuration ($m), 2008-14 46
Figure 17: Mitsubishi Tanabe prescription pharmaceutical sales by molecule type ($m), 2002-14 47
Figure 18: Mitsubishi Tanabe prescription pharmaceutical sales by source ($m), 2002-14 49
Figure 19: Mitsubishi Tanabe operating revenue/cost analysis ($m), 2002-14 53
[Inhaltsverzeichnis ausblenden]
